{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=12", "query": { "intervention": "Arm 2- Dose Expansion", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:04:15.472Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07061938", "title": "Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IgG4 Related Disease" ], "interventions": [ { "name": "ACE1831", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acepodia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2026-01-01", "completion_date": "2029-09-20", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061938" }, { "nct_id": "NCT05650632", "title": "A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig (ABBV-383)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2023-03-21", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hinsdale", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650632" }, { "nct_id": "NCT01656642", "title": "A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-08-13", "completion_date": "2020-03-25", "has_results": false, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656642" }, { "nct_id": "NCT06844214", "title": "A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myotonic Dystrophy" ], "interventions": [ { "name": "SAR446268", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "10 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2025-07-23", "completion_date": "2032-04-27", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 5, "location_summary": "Gainesville, Florida • Tampa, Florida • New York, New York + 2 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06844214" }, { "nct_id": "NCT06255028", "title": "A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis", "Idiopathic Inflammatory Myopathies", "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "CNTY-101", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Century Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 6, "start_date": "2025-02-06", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06255028" }, { "nct_id": "NCT04180371", "title": "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor Historically Known for High EphA2 Expression", "Urothelial Cancer", "Ovarian Cancer", "Non-small Cell Lung Cancer", "Head and Neck Cancer", "Triple Negative Breast Cancer", "Gastric/Upper Gastrointestinal Cancer" ], "interventions": [ { "name": "BT5528", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BicycleTx Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2019-11-07", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 12, "location_summary": "Encinitas, California • Orange, California • Denver, Colorado + 9 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180371" }, { "nct_id": "NCT02734615", "title": "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic ER+ Breast Cancer" ], "interventions": [ { "name": "LSZ102", "type": "DRUG" }, { "name": "LEE011", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2016-06-14", "completion_date": "2021-09-13", "has_results": false, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734615" }, { "nct_id": "NCT02107963", "title": "A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Osteosarcoma", "Neuroblastoma", "Melanoma" ], "interventions": [ { "name": "Anti-GD2-CAR engineered T cells", "type": "BIOLOGICAL" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 15, "start_date": "2014-02-28", "completion_date": "2017-01-31", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107963" }, { "nct_id": "NCT03428958", "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Tumors", "Neoplasms, Colorectal" ], "interventions": [ { "name": "NUC-3373 + leucovorin", "type": "DRUG" }, { "name": "NUC-3373", "type": "DRUG" }, { "name": "NUFOX", "type": "DRUG" }, { "name": "NUFOX + VEGF pathway inhibitor", "type": "DRUG" }, { "name": "NUFOX + EGFR inhibitor", "type": "DRUG" }, { "name": "NUFIRI", "type": "DRUG" }, { "name": "NUFIRI + VEGF pathway inhibitor", "type": "DRUG" }, { "name": "NUFIRI + EGFR inhibitor", "type": "DRUG" }, { "name": "NUC-3373 + bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NuCana plc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-10-05", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428958" }, { "nct_id": "NCT03830918", "title": "Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Extensive Stage Lung Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2019-03-06", "completion_date": "2027-01-03", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-15T17:04:15.472Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03830918" } ] }